R727 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
79Homozygous familial hypercholesterolemia1

79. Homozygous familial hypercholesterolemia


Clinical trials : 145 Drugs : 114 - (DrugBank : 26) / Drug target genes : 8 - Drug target pathways : 17
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-000351-95-IT
(EUCTR)
12/10/201709/02/2021A study to the safety and efficacy of Alirocumab in patients with hereditary abnormal (high) cholesterol levelA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the efficacy and safety of Alirocumab in patients with Homozygous Familial Hypercholesterolemia - ODYSSEY HoFH Homozygous Familial Hypercholesterolemia
MedDRA version: 20.0;Level: LLT;Classification code 10057080;Term: Homozygous familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Praluent
Product Name: R727
Product Code: [R727]
INN or Proposed INN: Alirocumab
Other descriptive name: Alirocumab
REGENERON PHARMACEUTICALS, INC.NULLNot RecruitingFemale: yes
Male: yes
55Phase 3United States;Czechia;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Denmark;South Africa;Germany